DM 5167
Alternative Names: DM-5167Latest Information Update: 30 Jun 2023
At a glance
- Originator Kainos Medicines
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 05 Jun 2023 DM 5167 is available for licensing as of 01 Jun 2023. http://kainosmedicine.com/?c=user&mcd=eng02_05
- 14 Apr 2023 Preclinical trials in Triple-negative breast cancer in South Korea (PO)
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Triple negative breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)